RCS - Theracryf PLC - TheraCryf Research and Development Day

TheracryfAnnouncement

13/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240613:nRSM2073Sa&default-theme=true

RNS Number : 2073S  Theracryf PLC  13 June 2024

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

TheraCryf Research and Development Day - 13 June 2024

 

Alderley Park, 13 June 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma
plc, the clinical stage drug development company focussing on oncology and
neuropsychiatry, announces that it is holding a Research and Development
update event today at 09:30am.

 

The management team and external speakers will be providing an update on
TheraCryf, including the Chronos acquisition and update on the integration;
discussion about the clinical programme in glioblastoma and the preclinical
programmes in neuropsychiatry. The session will also include a discussion
about market potential and the ongoing strategy.

 

Speakers will include members of the TheraCryf (and former Chronos) management
and scientific team, and external speakers including Dr Marjolein Geurts,
neuro-oncologist and Dr Wouter Vanbilloen MD, neurology resident from Erasmus
University Medical Center.

 

Please note that the Erasmus team will provide a new update from their
research on the combination of SFX-01 and radiation in certain glioblastoma
cells derived from patients. They have observed a positive combination effect
of SFX-01 and radiation which has also been observed with SFX-01 in laboratory
models of glioblastoma in other centres.

 

The event will be held at the offices of Instinctif Partners located at 65
Gresham Street, London EC2V 7NQ
(https://www.google.com/maps/place/65+Gresham+St,+London+EC2V+7NQ/@51.5156778,-0.0959812,17z/data=!3m1!4b1!4m6!3m5!1s0x48761caaa591a275:0x3305ebe7e1393dc5!8m2!3d51.5156745!4d-0.0934063!16s%2Fg%2F11csm28sny?entry=ttu)
and is open to sell-side analysts and all existing and potential shareholders.
Investors and analysts will be able attend the event in person (please
register at TheraCryf@instinctif.com) or virtually via the Investor Meet
Company platform HERE
(https://www.investormeetcompany.com/theracryf-plc/register-investor) .

 

- Ends-

 

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Cavendish Capital Markets (NOMAD and Broker)                +44 20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

 Instinctif Partners                                         +44 207 457 2020

theracryf@Instinctif.com
 Melanie Toyne-Sewell / Jack Kincade

 

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications such as neurodevelopmental disorders, glioblastoma*, addiction,
anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate
compelling data sets to proof of concept and/or later phase II to partner its
clinical programmes with mid-size to large pharma. As well as a number of
industry partnerships with companies, including Stalicla, in neurodevelopment
disorders and has sourced programmes from companies such as Takeda and Shire,
the Company has worked with and has ongoing collaborations with major
universities, hospitals and government organisations such as the University of
Manchester, Sapienza (Università di Roma), Kings College London and
University of Connecticut.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C%3A/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKBBPPBKDOAD